Topics
-
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
-
Implementing the Group’s Social Contribution Activity: “Sysmex Gives Back Day”
-
Business Results Announcement for the Fiscal Year Ending March 31, 2020 (See Latest Financial Statements)
-
Updated : Sysmex Report 2019
-
Development of a Fully Automated Measurement Method for Soluble Immune Checkpoint Molecules (sPD-1, sPD-L1 and sCTLA-4)
-
Updated : Sysmex Sustainability Data Book 2019
Press Releases
-
Sysmex Receives Regulatory Approval in China of an in Vitro Diagnostic Reagent to Help Diagnose Breast Cancer Lymph Node Metastasis Using the OSNA™ Method
-Aiming to Introduce a System to Test for Breast Cancer Lymph Node Metastasis into the Chinese Market- -
Sysmex Launches Gene Testing Kit for Blood Cancer (ipsogen JAK2 DX Reagent)
First Insurance Coverage in Japan for JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms -
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - -
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
-Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference- - Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2020 (PDF：374KB)
